Taking one tablet every morning sounds easy. Now imagine doing it tomorrow, next year, and every year after that.
That is the reality of modern HIV treatment. Today’s antiretroviral medicines can reduce the amount of virus in the blood to an undetectable level and keep it there for years. People who maintain viral suppression can live long, healthy lives. They also do not transmit HIV through sex—a well-established principle known as U=U, or undetectable equals untransmittable.
The medicine works exceptionally well. Living with a daily reminder of HIV can be harder.
A pill bottle may need to be hidden from a roommate. Medication has to be packed for every trip. A delayed flight, an unexpected night away, or a simple change in routine can turn an ordinary dose into something that requires planning.
Now researchers are studying a different schedule: one tablet a week.
The experimental combination contains islatravir and lenacapavir, two long-acting antiviral drugs that interfere with HIV in different ways. Recent Phase 3 results suggest that adults with an already suppressed viral load can switch from daily therapy to the weekly tablet without sacrificing viral control.
That is a meaningful result. It is not the same as FDA approval.
Islatravir/lenacapavir remains investigational as a weekly HIV treatment. It is not currently available from pharmacies, and nobody taking HIV medication should stop or change treatment while waiting for it.
Still, the research has reached the point where a weekly oral regimen looks less like a distant idea and more like a possible addition to HIV care.
Why taking fewer pills could make a difference
Consider two people who have both maintained an undetectable viral load for five years.
The first takes a tablet while brushing his teeth each morning. The habit is automatic. He rarely thinks about it and sees little reason to change.
The second travels regularly for work. He checks his bag several times before leaving home, worries about running out during a delayed trip, and dislikes carrying a labeled medicine bottle through airport security.
Their laboratory results may look identical. Their experience of treatment does not.
A weekly HIV pill could reduce the number of times treatment enters a person’s day. Instead of opening a bottle every morning, a patient might choose one regular evening, set a reminder, and then go six days without thinking about the next dose.
For some people, that could provide more privacy. It may also reduce the emotional weight of taking lifelong medication. Even when a daily tablet causes no physical side effects, swallowing it can act as a small reminder of a diagnosis the person would rather not revisit before breakfast.
A weekly tablet may also appeal to patients who want a long-acting treatment but do not want injections. Long-acting injectable HIV therapy is already an option for selected patients, but it involves scheduled clinic visits and injections into a muscle. A tablet taken at home would occupy the space between daily pills and less frequent injections.
Weekly treatment will not suit everyone, though.
Daily routines benefit from repetition. A tablet taken with coffee each morning can become almost impossible to forget. A medicine reserved for Sunday evening may slip from memory when the weekend becomes busy.
Fewer doses do not automatically guarantee better adherence. The real advantage is having another choice.
How islatravir and lenacapavir work
Effective HIV treatment usually combines medicines that attack the virus at different stages. This makes it more difficult for HIV to continue replicating and helps prevent drug resistance.
Islatravir and lenacapavir follow that strategy, but both remain active in the body long enough to support weekly dosing.
Islatravir interferes with reverse transcriptase, an enzyme HIV needs after entering a human cell. The virus uses this enzyme to convert its genetic instructions into DNA. Islatravir interrupts that copying process and prevents HIV from completing functional viral DNA.
Its formal classification is a nucleoside reverse transcriptase translocation inhibitor. The terminology sounds complicated, but the basic idea is simple: HIV is trying to copy itself, and islatravir disrupts the copying machinery.
Lenacapavir attacks a different target.
It binds to the HIV capsid, the protective protein shell surrounding the virus’s genetic material. The capsid plays a role during several stages of the viral life cycle. HIV needs it when delivering genetic material into a cell and again when assembling new virus particles.
By disrupting the capsid, lenacapavir can interfere with HIV at multiple points.
The combination therefore approaches HIV from two directions. Islatravir interferes with viral DNA production, while lenacapavir disrupts the protective structure HIV needs to reproduce successfully.
That does not mean other antiviral drugs can be substituted for either medicine. “Antiviral” describes a broad drug category, not a group of interchangeable products. A medicine designed for herpes, influenza, or COVID-19 will not automatically work against HIV.
Our guide to how antiviral medications work explains why different viral infections require different drugs.
What happened in the Phase 3 trials?
The latest evidence comes from two studies called ISLEND-1 and ISLEND-2.
Both were switch studies. Researchers enrolled adults who were already receiving stable HIV treatment and had maintained a viral load below 50 copies per milliliter for at least six months.
That detail matters.
These trials did not study the weekly pill as a first treatment for someone newly diagnosed with HIV. They also did not test it as a rescue therapy for people whose current regimen was failing. Participants entered the research with HIV already under control.
ISLEND-1 involved 607 adults from 12 countries. Participants were randomly assigned either to switch to once-weekly islatravir/lenacapavir or to remain on daily bictegravir/emtricitabine/tenofovir alafenamide, commonly sold under the brand name Biktarvy.
After 48 weeks, none of the participants assigned to weekly islatravir/lenacapavir had a viral load at or above 50 copies/mL under the FDA snapshot analysis.
In the Biktarvy group, one participant—0.3%—reached or exceeded that level.
The study found that the weekly regimen was noninferior to daily Biktarvy. “Noninferior” does not necessarily mean better. It means that the experimental treatment did not perform unacceptably worse than the established comparison within a limit researchers selected before the trial began.
The full ISLEND-1 results were published in the New England Journal of Medicine:
https://www.nejm.org/doi/full/10.1056/NEJMoa2607973
ISLEND-2 used a broader comparison. Instead of having everyone in the daily-treatment group take Biktarvy, participants continued one of several guideline-recommended two- or three-drug regimens.
At week 48, 0.3% of people receiving the weekly combination had HIV RNA at or above 50 copies/mL. Among those who continued daily standard-of-care treatment, the figure was 1.3%.
The weekly regimen once again met the trial’s standard for noninferiority.
Participants who switched also reported greater treatment satisfaction and a lower treatment burden. That finding is subjective, but it remains relevant. Treatment has to work biologically; it also has to fit into a person’s life.
The results are encouraging, but 48 weeks is not the end of the story. Longer follow-up should provide more information about durability, safety, and the possibility of resistance over time.
What side effects were reported?
The two Phase 3 trials produced somewhat different safety comparisons.
In ISLEND-1, treatment-related adverse events were reported by 13.5% of participants receiving islatravir/lenacapavir and 13.2% of those continuing Biktarvy. The rates were nearly identical.
Headache and nausea were the most commonly reported treatment-related problems, each affecting approximately 3% of participants.
Stopping treatment because of an adverse event was uncommon. It occurred in 2% of people taking the weekly combination and 1.7% of those receiving Biktarvy.
ISLEND-2 produced a wider difference.
Treatment-related adverse events were reported in 18% of participants who switched to the weekly combination and in fewer than 1% of those who remained on their existing daily treatment. Headache was reported in approximately 5% of weekly-treatment participants, while nausea and diarrhea each occurred in about 3%.
Why did the trials look so different?
Study design may have played a part. ISLEND-1 was double-blind and used matching placebos. Participants did not know which active regimen they were receiving.
ISLEND-2 was open-label. Everyone knew who had switched to the new weekly medicine. When patients begin a visible new treatment, they may pay closer attention to headaches, digestive symptoms, or other changes and may be more likely to connect them with the drug.
That does not make the symptoms unimportant. It simply means the 18% figure should not be viewed in isolation.
Only around 1% of participants in the weekly group stopped treatment because of an adverse event in ISLEND-2.
Researchers also monitored CD4 cells and total lymphocyte counts. These remained stable through 48 weeks, and no participant discontinued because of a decline in either measure.
That finding deserves attention because earlier development of higher islatravir doses raised concerns about decreases in certain immune cells. The weekly combination studied in ISLEND-1 and ISLEND-2 uses 2 mg of islatravir with 300 mg of lenacapavir.
No new safety concern was identified with this dose during the first 48 weeks. Longer follow-up remains necessary.
What happens when a weekly dose is missed?
One pill a week sounds simple until someone forgets it.
Suppose a patient normally takes the medicine on Sunday evening but remembers on Monday morning. The eventual prescribing information should explain whether the dose can be taken immediately and when the next tablet should follow.
Remembering on Wednesday could be a different situation. Missing more than one week may require another plan entirely.
Patients should not apply missed-dose instructions from a daily HIV medicine to a long-acting weekly combination. The acceptable window, procedure for restarting, and possible need for additional doses will need to come from the approved label and the treating clinician.
Trial participants did not simply begin taking one tablet every seven days. They received initial doses on days one and two, followed by weekly treatment beginning on day eight. This loading schedule helps establish sufficient drug concentrations.
That alone shows why restarting after a longer interruption should not be improvised.
HIV can develop resistance when drug exposure becomes inadequate. With a long-acting combination, one medicine may also remain in the body longer than its partner. If the virus is exposed to too little active treatment, it may begin replicating under conditions that favor resistant variants.
A weekly schedule will therefore require its own adherence routine.
A patient might use a phone alert, a calendar reminder, and a backup notification the following morning. Choosing a quiet weekday may be more reliable than choosing a busy Saturday. Some people may ask a partner or family member to share the reminder.
The pill is taken less frequently. Taking it on schedule still matters.
Drug interactions may limit who can use it
Lenacapavir is processed through several enzyme and transporter systems, including CYP3A and P-glycoprotein.
Medicines that strongly induce these systems can lower the amount of lenacapavir in the body. If the concentration falls too far, the combination may no longer suppress HIV reliably.
Before switching treatment, a clinician or pharmacist would need to review everything the patient takes. That includes prescriptions, nonprescription medicines, vitamins, herbal products, and bodybuilding supplements.
Patients should not assume that the interaction guidance for another lenacapavir product will apply word for word to the weekly combination. The formulation, dose, partner drug, and purpose of treatment all matter.
A trusted online pharmacy can make obtaining approved prescriptions more convenient, but HIV treatment requires more than delivering a medicine bottle. Patients need viral-load monitoring, interaction screening, resistance review, and regular care from a clinician experienced in treating HIV.
Islatravir/lenacapavir cannot currently be purchased as an approved weekly HIV treatment. Any seller claiming otherwise is offering something outside the legitimate approval and distribution process.
Patients researching medicines used for other viral infections can view available antiviral treatment options. These products are intended for specific infections and cannot substitute for antiretroviral therapy.
Is the weekly pill a type of PrEP?
No.
The islatravir/lenacapavir combination discussed here is being developed as treatment for people who are already living with HIV. The Phase 3 participants had an undetectable viral load before switching.
PrEP—pre-exposure prophylaxis—is used by HIV-negative people to reduce the risk of acquiring HIV.
Treatment and prevention are not interchangeable. An experimental treatment combination should not be used as homemade PrEP, while a medicine approved only for prevention may not provide complete treatment for someone who already has HIV.
The confusion is understandable because lenacapavir has been studied in different formulations and for different purposes. Seeing the same active ingredient in two headlines does not mean the products have identical doses, schedules, or uses.
The weekly tablet is not a cure either.
Antiretroviral therapy prevents HIV from reproducing and protects the immune system. It does not remove every copy of the virus from the body. HIV can remain hidden in latent reservoirs even when routine tests show an undetectable viral load.
If effective treatment is stopped for long enough, the virus can rebound.
Weekly dosing would change how often medicine is taken. It would not eliminate the need for continuing treatment.
Who might eventually be able to switch?
If regulators approve the combination using the current evidence, its first use will probably resemble the circumstances studied in the trials.
A likely candidate would be an adult who has maintained an undetectable viral load on stable oral treatment and wants a less frequent option. The person would also need to have no known resistance or drug interaction that would weaken the new regimen.
Doctors would review previous resistance tests, current medications, adherence history, and hepatitis B status before recommending a switch.
Hepatitis B requires particular attention. Several widely used HIV regimens contain drugs that suppress both HIV and hepatitis B virus. If a patient with hepatitis B stops those medicines without another hepatitis B treatment plan, the virus may become active again and cause liver inflammation.
The current evidence is less complete for people who are newly diagnosed, pregnant, younger than 18, living with uncontrolled HIV, or managing complicated drug resistance.
That does not prove that the weekly combination will be unsuitable for every person in these groups. It means the Phase 3 switch trials were not designed to answer those questions.
Will weekly treatment replace daily pills?
It is unlikely to replace them completely.
Daily HIV treatment is effective, familiar, and convenient for millions of people. Someone who has remained undetectable for years, tolerates the medicine well, and rarely misses a dose may have no reason to change.
A weekly tablet would add another option rather than make daily therapy obsolete.
Some patients will prefer the security of a routine they repeat every morning. Others may choose long-acting injections because they do not want to keep HIV medicine at home. A weekly pill could suit people who want fewer treatment days but still prefer oral medicine over injections.
Cost and access will matter too.
A scientifically impressive treatment has limited practical value if insurance does not cover it or pharmacies cannot supply it consistently. Copayments, prior authorization, specialist dispensing, and local availability could all influence its eventual use.
People comparing different ways of obtaining their other prescriptions can read our guide to choosing an online drugstore or retail pharmacy. HIV medicines should always come through a regulated supply chain coordinated with the prescribing clinic.
What happens now?
The manufacturers have said the Phase 3 findings will support regulatory submissions.
Regulators will review more than the headline viral-load numbers. They will examine the complete safety database, resistance outcomes, drug interactions, manufacturing standards, longer-term results, and proposed instructions for starting or restarting treatment.
Approval is possible, but it is not guaranteed. A reliable availability date cannot be given until regulatory agencies complete their reviews.
For now, anyone taking daily HIV treatment should continue the prescribed regimen. Stopping medicine while waiting for a weekly alternative could allow the virus to rebound and may create resistance that limits future treatment choices.
The significance of islatravir/lenacapavir is not that daily treatment has failed. Daily therapy works so well that researchers can now concentrate on making effective treatment easier to live with.
One pill a week will not be the right choice for everybody.
For someone who wants fewer reminders, more privacy, and no injections, however, it could become a genuinely useful option.
